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Abstract
Background: The International Prognostic Index (IPI) is used to determine prognosis in diffuse
large B-cell lymphoma (DLBCL). One of the determinants of IPI is the stage of disease with bone
marrow involvement being classified as stage IV. For the IPI, involvement on bone marrow is
traditionally defined on the basis of histology with ancillary investigations used only in difficult cases
to aid histological diagnosis. This study aimed to determine the effect of the routine use of flow
cytometry, immunohistochemistry and molecular studies in bone marrow staging upon the IPI.
Results: Bone marrow trephines of 156 histologically proven DLBCL cases at initial diagnosis were
assessed on routine histology, and immunohistochemistry using two T-cell markers (CD45RO and
CD3), two B-cell markers (CD20 and CD79a) and kappa and lambda light chains. Raw flow
cytometry data on all samples were reanalysed and reinterpreted blindly. DNA extracted from
archived paraffin-embedded trephine biopsy samples was used for immunoglobulin heavy chain and
light chain gene rearrangement analysis. Using immunophenotyping (flow cytometry and
immunohistochemistry), 30 (19.2%) cases were upstaged to stage IV. A further 8 (5.1%) cases were
upstaged using molecular studies. A change in IPI was noted in 18 cases (11.5%) on
immunophenotyping alone, and 22 (14.1%) cases on immunophenotyping and molecular testing.
Comparison of two revised IPI models, 1) using immunophenotyping alone, and 2) using
immunophenotyping with molecular studies, was performed with baseline IPI using a Cox
regression model. It showed that the revised IPI model using immunophenotyping provides the best
differentiation between the IPI categories.
Conclusion: Improved bone marrow staging using flow cytometry and immunohistochemistry
improves the predictive value of the IPI in patients with DLBCL and should be performed routinely
in all cases.
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Background
Diffuse large B-cell lymphoma (DLBCL) is defined by the
World Health Organization (WHO) as a heterogeneous
entity, encompassing morphologic and genetic variants,
and variable clinical presentations and outcomes [1]. It
accounts for 80% of all aggressive lymphomas [1]. The
median long-term overall survival in DLBCL is only ~40-
50% [2] with variable outcomes depending on pre-treat-
ment clinical and laboratory characteristics [3].
The International Prognostic Index (IPI) is a standard clin-
ical tool that is widely used to predict outcome for
patients with aggressive Non-Hodgkin lymphoma (NHL),
including DLBCL. It uses a number of clinical and labora-
tory markers present at the time of diagnosis to predict
survival. Age > 60 years, stage III/IV disease defined by
results of radiological investigations and bone marrow
(BM) biopsy, elevated lactate dehydrogenase (LDH) level,
Eastern Cooperative Oncology Group (ECOG) perform-
ance status ≥ 2 and more than one extra nodal site of dis-
ease, are scored 1 each, and depending on the final score
ranging from 0-5, 4 prognostic categories are created.
These are: low risk correlating with IPI of 0-1, low-inter-
mediate risk with IPI of 2, high-intermediate risk with IPI
of 3, and high risk with IPI of 4-5. Five year overall surviv-
als range from 73% to 26% [3]. However, limitations of
the IPI are well recognised owing to the heterogeneity in
clinical outcomes within IPI groups. Although gene
expression profiling has been used to determine subtypes
of DLBCL based on stages of B-cell differentiation [4],
such studies are largely limited to the research setting.
Efforts to improve clinical outcomes in DLBCL using reli-
able prognostic markers are ongoing [5,6]. In this study,
we assessed the impact of improved staging investigations
using easily available ancillary investigations on the IPI.
BM involvement was defined using histology alone in the
large multicentre study from which the IPI was developed
[3]. Ancillary tests such as flow cytometry, immunohisto-
chemistry and molecular studies were not considered as
part of staging towards the IPI. As these investigations
have become more routinely available in laboratories
around the world and their usage has increased, attempts
have been made to define their clinical role. Currently the
practice of performing ancillary tests is variable, and
although several centres may perform at least some of
these tests in routine practice, their usage is not appropri-
ately validated and the impact of the routine use of these
tests on the IPI has not been formally studied. When
patients with histologically inapparent bone marrow
involvement have positive results on ancillary tests, there
is likely to be change in the IPI.
This study demonstrates that a significant change in the
predictive value of the IPI can be brought about by incor-
porating ancillary investigations over and above routine
histological diagnosis in staging bone marrows.
Methods
Patients
One hundred and fifty six retrospective cases diagnosed
with histologically proven DLBCL at the Canberra Hospi-
tal from 1986-2005, on whom staging BM biopsies had
been performed, were identified for the purpose of the
study. After approval was obtained from the Australian
Capital Territory (ACT) Human Research Ethics Commit-
tee, clinical information on patients was collected from
the medical records department at The Canberra Hospital.
The average age of the patient cohort was 61 years (range
20-87 years), and the male to female ratio was 1.5:1. Base-
line staging data using routine staging procedures [com-
puted tomography (CT) scan, gallium/positron emission
tomography (PET) scan and histological examination of
BM] was available in 150 patients. Thirty nine (26%), 35
(23%), 45 (30%), and 31 (21%) were found to have stage
I, stage II, stage III and stage IV disease respectively. Base-
line assessment of IPI was possible in 148 patients. Thirty
seven (25%) had an IPI of ≤ 1 of which 14 (9.5%) had an
IPI of 0, and 23 (15.5%) an IPI of 1. IPIs of 2 and 3 were
noted in 36 (24.3%) and 46 (31.1%) cases respectively.
Twenty nine (19.6%) cases had an IPI of ≥ 4 of which 22
(14.9%) and 7 (4.7%) and an IPI of 4 and 5 respectively.
The mean baseline IPI of the patient cohort was 2.41 with
a standard deviation of 1.3.
Treatment data showed that of 152 patients on whom
data was available, most were treated with anthracycline
based regimens. One hundred and twenty nine patients
(82.7%) were treated with Cyclophosphamide, Doxoru-
bicin, Vincristine and Prednisolone (CHOP) [7] or varia-
tions of CHOP chemotherapy protocols [8,9]. Two
patients were treated with Ifosphamide, Carboplatin and
Etoposide (ICE) [10], 5 patients with Prednisolone,
Etoposide and Novantrone (PEN) [11], 1 with Etoposide,
Vincristine, Doxorubicin, Cyclophosphamide and Pred-
nisolone (EPOCH) [12], 2 with Hyper-CVAD [13] com-
prising of hyperfractionated Cyclophosphamide,
Vincristine, Doxorubicin and Prednisolone courses alter-
nating with courses of Methotrexate and Cytarabine, 3
with Trans-Tasman Radiation Oncology group (TROG)
protocol [14] and 1 with Methotrexate, Doxorubicin,
Cyclophosphamide, Vincristine, Prednisolone and Bleo-
mycin (MACOP-B) [15]. Nine patients were treated with
palliative intent with steroids alone or in combination
with non-anthracycline based drugs. Treatment details
were not available in 2 patients and 2 were lost to follow-
up. Thirty six patients (22.2%) received Rituximab. The
median overall survival of the entire patient group was 6
years (95% confidence interval [CI]: 3.8, 8.4 years).Journal of Hematology & Oncology 2009, 2:49 http://www.jhoonline.org/content/2/1/49
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BM histology
BM biopsies are performed as a routine assessment for all
cases with DLBCL at first diagnosis in our institution. All
trephines are fixed in buffered formalin and acetic acid for
24 hours and then decalcified using 5% nitric acid. Sam-
ples are then embedded in paraffin and sections stained
with Haematoxylin and Eosin (H&E), giemsa stain and
silver impregnation for reticulin. Archived H&E, giemsa
and reticulin preparations on the trephine biopsy were
retrieved for review. The mean trephine length for the
patient cohort was similar to our previous reports, 17.6
mm with a range of 8-36 mm and the mean number of
levels on H&E sections were 3.7 (range 1-8).
Two haematologists reviewed all slides blindly, and dis-
crepant cases (n = 20) were resolved by consensus. Stand-
ardised criteria were used to classify trephine biopsy
samples as positive, negative or indeterminate [16].
Flow cytometry
Raw immunophenotypic data on all bone marrow biop-
sies was retrieved from laboratory records and re-ana-
lysed.
Multiparametric flow cytometric analysis is performed in
our laboratory, with marrow cells immunophenotypically
labelled by direct four-colour immunofluorescence using
a panel of antibodies (CD45, CD19, CD20, CD22, CD10,
HLA-DR, Kappa, Lambda, CD2, CD3, CD5, CD7; Becton-
Dickinson).
Red cells are lysed by incubation with ammonium chlo-
ride, and cells washed in phosphate buffered saline after
centrifugation. A cell-suspension of 1 × 106 cells per tube
is incubated with the monoclonal antibody at room tem-
perature, then washed and resuspended in a solution of
phosphate buffered saline and foetal calf serum. Isotypic
controls used are IgG1 and IgG2.
Data acquisition is on a Becton-Dickinson flow cytometer
with a minimum of 2000 lymphocytes counted in each
sample. Bright CD45 fluorescent staining and intermedi-
ate side scatter are employed as the primary gating strate-
gies to identify the lymphocyte population, and further
gating is performed as required based on cell size or using
back gating on CD19 positive events.
Previously archived raw data were reanalysed, including
blinded re-determination of the population of lym-
phocytes to be gated. Positive results on flow cytometry
were defined as light chain clonal restriction with a kappa:
lambda ratio of >3:1 or <0.3:1[17]. Predominance of B-
cells in the gated population alone without light chain
restriction was not considered as a positive result.
Immunohistochemistry
Immunohistochemical analysis was performed on a Ven-
tana Benchmark NexES machine. Sections from archived
formalin-fixed decalcified paraffin-embedded (FFDPE)
trephine biopsies were immunostained using the strepto-
vidin-biotin method. The following monoclonal antibod-
ies were used: CD3 [Dako clone CD3, 1:200 dilution],
CD45RO [Novacastra clone UCLH-1, 1:1000 dilution],
CD20 [Zymed clone L26, 1:50 dilution], CD79a [Dako
clone JCB117, 1:500 dilution], Kappa [Novacastra clone
kp-53, 1:750 dilution], and Lambda [Novacastra clone
Hp-6054, 1:750 dilution]. All antibodies are validated
and routinely used in our laboratory. CD20 and CD3 are
reported to be sensitive at assigning lineage in diffuse
aggressive NHL [18] and CD79a and CD45RO were
selected over others owing to familiarity and to maintain
consistency. These are the antibodies used for diagnostic
tissue sections in our laboratory. Heat retrieval was used
for all antibodies and tonsillar tissue was used as a posi-
tive control. A standardised system of reporting was
adopted and was followed for all stains by two patholo-
gists blinded to previous assessment on histology.
Features used to define involvement on immunohisto-
chemistry reflected standardised histology criteria. The
presence of B-cell aggregates was classified as abnormal or
malignant when there were large numbers of aggregates,
the aggregates were large-sized, or contained dispropor-
tionate numbers of larger cells. Controls (six morpholog-
ically normal marrows) were used to create a visual
impression of normal amounts of background T and B-
cells. Scattered small or large B-cells were classified posi-
tive only when the numbers were substantially increased
as compared to controls. A conservative approach was
adopted to avoid false positives. Discrepancies between
the two pathologists were resolved consensually.
Molecular studies
Samples for molecular studies were obtained from forma-
lin-fixed decalcified paraffin-embedded (FFDPE) trephine
sections. DNA extraction was performed manually using
the Roche High Pure PCR Template Preparation Kit from
two 10-micron FFDPE trephine sections according to the
manufacturer's instructions. To verify the integrity of the
DNA extracted from the paraffin sections, and to validate
results, all samples were amplified with the control master
mix provided in the Immunoglobulin heavy chain (IgH)
gene clonality kit from Invivo Scribe Technologies based
on the BIOMED2 protocols (IgH Gene Clonality Assay -
Gel Detection; InVivo Scribe Teachnologies, USA). This is
a multiplex PCR that targets multiple genes and generates
a series of amplicons 100, 200, 300, 400 and 600 base
pairs (bp) in length.Journal of Hematology & Oncology 2009, 2:49 http://www.jhoonline.org/content/2/1/49
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IgH gene rearrangement analysis was performed on all
cases, targeting the conserved framework regions (FR) FR1
[IGHA: VHFR1-JH] and FR3 [IGHC: VHFR3-JH] using the
Invivo scribe kit based on the BIOMED2 protocols [19].
Only FR1 and FR3 were analysed owing to limited
amounts of DNA and based on reports from other groups
[20]. This was combined with light chain gene rearrange-
ment analysis and included two reactions targeting Ig
Kappa (IgK) variable and joining regions [IGHKA: Vk-Jk;]
and IgK variable and intragenic regions [IGKB: Vk-Kde]. The
PCR reactions consisted of 45 μL of the FR1, FR3 or IGK
master mix solution, 2.5 units of Amplitaq Gold (Applied
Biosystems, USA) and 5 μl of template DNA (with an aver-
age template DNA concentration of 300-400 ng/μl).
Thermo cycling was performed according to the kit proto-
col with no modifications on a Perkin Elmer 9600 ther-
mocycler. Controls consisted of a positive DNA control,
negative extraction control and negative PCR control.
Water was used as a negative control in both cases.
Non-denaturing polyacrylamide gel electrophoresis was
used to resolve the FR1 and FR3 PCR products. 25 uL of
PCR product was loaded onto a 6% polyacrylamide gel
and 250 V applied for 1.25 hours for FR1 and 1.5 hours
for FR3 reactions. After electrophoresis, the gels were
stained with ethidium bromide and visualised under UV
light.
For the IGK reactions, PCR products were denatured at
94°C for five minutes and subsequently cooled at 4°C for
60 minutes to induce duplex formation. Non-denaturing
polyacrylamide gel electrophoresis was used to resolve the
PCR products. 25 uL of PCR product was loaded onto a
6% polyacrylamide gel and 250 V applied for 1.5 hours
each for both reactions.
FR1, FR3 and IgK gene rearrangements were reported as
clonal, polyclonal or not detected. The expected sizes of
the PCR products were 310-360 bp for FR1 and 100-170
bp for FR3 which together are estimated to account for
approximately 70% of all rearrangements [20] IGK PCR
products were expected to be in the following ranges: 120-
160 bp, 190-210 bp, 260-300 bp for IgKA and 210-250,
270-300, 350-390 bp for IgKB.
Statistical analysis
Survival data were recorded for each patient. Besides
descriptive analysis, Kaplan Meier curves were created
with cumulative survival as the outcome. Forward step-
wise multivariate Cox regression analysis using the likeli-
hood ratio method was used to establish a comparison
between baseline IPI and two revised IPI models. The first
model (rIPI1) was based on routine use of immunophe-
notyping alone (flow cytometry and immunohistochem-
istry) and the second (rIPI2) was based on routine use of
immunophenotyping and molecular results. A probabil-
ity of 0.05 was used as the entry criterion and 0.1 was con-
sidered for removal. Patients treated with palliative intent
were excluded from all survival analyses. All analyses were
performed using the software programme Statistical Pack-
age for Social Sciences (SPSS) version 14.0.
Results
Histology
Of the 156 cases on which bone marrow histology slides
were available, 24 were positive on routine histology. Six
cases were reported as indeterminate using Cheson crite-
ria, and agreed upon as being positive for involvement
after consensual review. H&E stains showed no evidence
of involvement in 126 cases.
Immunophenotyping
Flow cytometry data was evaluable in 152 cases, of which
27 (17.3%) cases were noted to be positive for involve-
ment using standardised light chain ratios. Ten of these 27
cases were also positive on routine histology.
Immunohistochemistry using T and B-cell markers
showed involvement in 43 cases of 154 available cases of
which involvement on routine histology was noted in 25/
42 cases. One case was not comparable due to loss of H&E
slides. Flow cytometry and immunohistochemistry each
detected histologically inapparent involvement in 17
cases (11%).
Molecular studies
Amplification was obtained in 133/155 cases (84.7%)
with amplification at 96 base pairs (BP), 200 bp, 300 bp,
400 bp and 600 bp noted in 125 (79.6%), 74 (47.1%), 32
(20.4%), 25 (15.9%) and 18 (11.5%) cases respectively.
Forty one cases of 155 evaluable ones were positive on
immunoglobulin heavy and light chain gene analysis.
Three showed no amplification on amplification controls.
Thirty four cases were positive on light chain analysis with
all showing a clonal band with kappa A; three cases also
showed clonal reactions with kappa B. Overall, 19 cases
were positive on heavy chain analysis (FR3: 18 cases, and
FR1: 4 cases) Of these, three cases were positive on both
reactions. Overlap with light chain analysis is shown in
table 1. Overall, 12/41 cases were positive and 29 negative
on routine histology.
To establish tumour origin, DNA was extracted from 17
available primary FFDPE tissue blocks and gene rearrange-
ment analysis performed. Comparable clonal bands could
be identified in only 10 cases. Of these, 2 were positive on
routine histology.
Thus, using stringent criteria to account for false positiv-
ity, routine molecular staging on FFDPE trephine biopsyJournal of Hematology & Oncology 2009, 2:49 http://www.jhoonline.org/content/2/1/49
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tissue yielded positive results in eight (5.1%) histologi-
cally negative cases.
Effect on stage and IPI
Thirty cases were upstaged using immunophenotyping
alone with 6 cases upstaged from stage I to IV, 12 from
stage II to IV, and 12 from stage III to IV. When molecular
results were added, two additional cases were upstaged
from stage I, 2 from stage II and 4 from stage III.
Two new revised IPI (rIPI) models were computed for all
cases. The first (rIPI1) was based on immunophenotyping
results alone i.e. flow cytometry and immunohistochem-
istry and the second (rIPI2) on immunophenotyping and
molecular results. Changes to the IPI essentially occurred
when stage of disease was upgraded from I or II to stage IV
diseases. Of 148 cases where IPI and rIPI were assessable,
three cases were upgraded from IPI 0 to a rIPI1 of 1, 4
cases of IPI 1 changed to a rIPI of 2, 5 cases of IPI 2 were
upgraded and 6 cases of IPI 3. No changes were noted in
IPI 4-5 group. Overall, 18 patients had a change in their
IPI. Of these, three changed their IPI from 0 to 1, which
was not apparent when only four prognostic categories
were considered. Incorporating molecular results, rIPI2
was found to be upgraded in 6, 7 and 6 cases of IPI 0-1, 2
and 3 respectively.
Survival
Kaplan Meier curves were created to assess the impact of
baseline IPI and the two new revised IPI models rIPI1 and
rIPI2 on overall survival. Figure 1 shows the cumulative
survival of the four IPI categories using a baseline IPI
model, a revised model using immunophenotyping
(rIPI1) and a revised model incorporating molecular stud-
ies and immunophenotyping (rIPI2) respectively. All
three models were statistically significant with p values of
< 0.0001.
Multivariate analysis
Using a multivariate forward stepwise (likelihood ratio
method) Cox regression, the three IPI models were com-
Table 1: Results on immunoglobulin heavy chain (IgH) and light 
chain (IgL) gene rearrangement studies
#IGK +ve IgK -ve Total
*FR3 +ve 13 5 18
**FR3 -ve 21 116 137
Total 34 121 155
FR1 +ve 2 2 4
FR1 -ve 32 119 151
Total 34 121 155
* FR1: framework I
** FR3: framework III
# IGK: immunoglobulin kappa
Figure 1
The three Kaplan Meier curves show differences in
cumulative survival between with low-risk, low-inter-
mediate, high-intermediate and high-risk categories
using a baseline IPI model (A) and two revised IPI
models. The first (rIPI1) incorporates flow cytometry and
immunohistochemistry as routine staging (B) and the second
IPI model (rIPI2) additionally incorporates molecular testing
using IgH/IgL analysis (C).Journal of Hematology & Oncology 2009, 2:49 http://www.jhoonline.org/content/2/1/49
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petitively considered for their contribution to predicting
survival. The score tests before inclusion into the model
were: Baseline IPI: 28.5 (df = 3, P < 0.001), rIPI1: 31.2 (df
= 3, p < 0.001) and rIPI2: 27.9 (df = 3, p < 0.001). The
revised rIPI1 model was then entered into the regression
model. The hazard ratios of dying relative to the 0/1 IPI
prognostic categories were: rIPI1 category 2 = 2.0 [95% CI,
0.61, 6.76, p = 0.248], rIPI1 category 3 = 7.6 [95% CI,
2.61, 22.36, p < 0.0001], rIPI1 category 4/5 = 8.9 [95% CI,
2.94, 27.17, p < 0.0001]. The baseline IPI model and rIPI2
models were excluded from the regression model because
they did not further contribute to explaining survival [p =
0.5, p = 0.6 respectively].
Table 2 provides a summary of the relative performances
of the three IPI models in predicting survival. It can be
seen that rIPI1 provides the best differentiation between
the IPI categories and the largest point estimate hazard
ratios.
To study the effect of treatment with Rituximab on sur-
vival, this too was considered, but not found to contribute
significantly to the Cox regression model (p:0.96).
Discussion
In this study, we have shown a significant improvement in
the predictive value of the IPI using ancillary staging
investigations, particularly immunophenotyping, on the
BM. By upstaging a proportion of cases, routine use of
immunophenotyping provides better differentiation
across the IPI prognostic categories. This has been con-
firmed using clinical outcomes in this study. These results
validate the current guidelines that recommend incorpo-
rating immunophenotyping in routine staging and sug-
gest the use of a new and more inclusive definition of BM
involvement within the IPI.
There have been several previous studies on the clinical
role of ancillary investigations such as flow cytometry
[17,21-25], and IHC [17,26,27] in NHL, although varia-
ble results are noted depending on the histological sub-
types of NHL.
Overall, multiparametric flow cytometry has been
reported to be more sensitive than histology alone, and
detection of flow cytometry positive cases have been
reported in 3-11% of histologically negative cases, with
rates in DLBCL varying from negligible to ~15% [17,21-
23,25]. The converse is also true and 5-20% histologically
positive DLBCL cases have been reported to be negative
on flow cytometry [17,21,22,25]. This may relate to a
number of factors such as sampling and adequacy of his-
tological diagnosis. Further development of multicolour
flow cytometry (6, 8 or 10 colour flow cytometry) and its
introduction into the clinical laboratory is likely to further
improve the sensitivity of this technique.
Similarly, IHC is reported to detect marrow involvement
in histologically negative cases in ~10-23% of cases
depending on the histological diagnosis and the antibod-
ies used [26,27]. This is considered to be due to examina-
tion of a greater number of levels and also to easier
detection of scattered malignant cells within normal hae-
mopoietic tissue.
Overall, we found that use of immunophenotyping i.e.
flow cytometry and immunohistochemistry in staging
bone marrow biopsies upstages ~20-22% of patients with
DLBCL. The two investigations complement each other.
Flow cytometry is generally performed on aspirate sam-
ples and can be expected to add independent prognostic
value. Immunohistochemistry, on the other hand, is per-
formed on the trephine. Although it does not add inde-
Table 2: Summary table showing the hazard ratios from Cox regression analyses for the three IPI models, baseline IPI, rIPI1 and rIPI2
rIPI1#
Hazard ratios
(95% CI)
Baseline IPI†
Hazard ratios
(95% CI)
rIPI2‡
Hazard ratios
(95% CI)
Low-risk IPI
(score 0/1)
Reference Reference Reference
Low-intermediate IPI
(score 2)
2.0 (0.61, 6.76)
p = 0.248
1.56 (0.54, 4.51)
P = 0.4
1.8 (0.5, 6.0)
P = 0.3
High-intermediate IPI
(score 3)
7.6 (2.61, 22.36)
p < 0.0001
5.32 (2.14, 13.22)
P < 0.0001
6.4 (2.2, 18.6)
P = 0.001
High-risk IPI
(score 4/5)
8.9 (2.94, 27.17)
p < 0.0001
6.9 (2.61, 18.32)
P < 0.0001
8.1 (2.7, 24.6)
P < 0.001
#Cox regression using forward likelihood ratio method (X2: 31.5, df = 3, p < 0.0001)
†Cox regression entering baseline IPI into the model first (X2: 27.4, df = 3, p < 0.0001)
‡Cox regression entering rIPI2 in to the model first (X2: 28.2, df = 3, p < 0.0001)Journal of Hematology & Oncology 2009, 2:49 http://www.jhoonline.org/content/2/1/49
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pendent prognostic value, it is a more sensitive technique
than histology alone. This study shows the value of incor-
porating these tests as a routine rather than using them in
histologically ambiguous cases only. Better differentiation
into low-risk, low-intermediate, high-intermediate and
high-risk IPI categories is obtained by using these tests on
all staging bone marrows.
There are several previous studies addressing the role of
gene rearrangement (IgH/IgL) studies [28-31] in NHL. Of
particular interest is the study by Mitterbauer-Hollander et
al which showed 16% of histologically negative cases had
clonal IgH and/or IgL genes within the bone marrow [31].
The authors demonstrated a significant difference in over-
all survival at 5 years amongst patients with positive his-
tology and molecular studies, negative histology but
positive molecular studies, and negative histology and
molecular studies. In our study, only ~5% of histologi-
cally negative cases were found to have rearranged immu-
noglobulin genes. We were unable to demonstrate a
difference in overall survival or a change in the predictive
value of the IPI by inclusion of molecular staging. This is
likely to be related to the unavailability of archived fresh
frozen trephine tissue or DNA for our study resulting in all
molecular analyses being performed on FFDPE trephine
tissue. This is in contrast to the previous study, in which
all molecular analyses were performed on fresh bone mar-
row aspirates [31]. It is well known that fresh tissue yields
better quality DNA compared to FFDPE tissue [32]. It
should also be noted that the BIOMED2 based protocols
are not as well established on FFDPE tissue [19], although
occasional groups have modified the protocols with
improved results [33]. It may be of interest to determine if
the use of such modified protocols would improve the
prognostic significance of molecular staging on FFDPE tis-
sue. Other alternatives to PCR staging may be staging
using Fluorescent in-situ hybridisation (FISH) probes
with some recent literature demonstrating that FISH using
IgH/BCL2 may give improved results as compared to PCR
on paraffin-embedded sections [34].
Besides the obvious advantage of availability of archived
trephine biopsy tissue, the other reason for choosing to
perform molecular staging on trephine biopsy rather than
aspirate is that histological bone marrow involvement is
noted more commonly on trephine biopsies. This has
been demonstrated in previous studies [35] and largely
attributed to sampling and the tendency of lymphoma
cells to adhere to bony trabeculae [36]. As such, there
would be greater likelihood of detecting clonal gene rear-
rangements on trephine biopsy rather than aspirate sam-
ples. Collecting additional trephine biopsy samples for
such testing may be logistically difficult. Improved DNA
extraction methods and optimal modification of the
BIOMED2 protocols for FFDPE trephine tissue may be the
best realistic option.
There are several limitations of our study. This is a small
retrospective study in DLBCL cases at initial diagnosis. As
only a proportion of cases were treated with Rituximab in
this study, we used multivariate analysis to demonstrate
that it was not a significant confounding factor in our
analysis. However, we acknowledge a prospective study
may be required to confirm that the results are valid in
Rituximab treated patients. The other major limitation is
the use of archived rather than fresh trephine tissue for
molecular staging due to the logistics of obtaining fresh
trephine tissue in our centre. We acknowledge that we
may have been able to demonstrate improvement in the
prognostic significance of the IPI using gene rearrange-
ment studies if fresh tissue had been analysed.
Despite the limitations of our study, we were able to dem-
onstrate an improvement in the prognostic significance of
the IPI by use of simple, relatively inexpensive and readily
available staging investigations such as flow cytometry
and IHC. Our results suggest that a large prospective study
is warranted to assess the impact of staging investigations
on the IPI in a more homogenously treated DLBCL popu-
lation.
Conclusion
￿ The predictive value of the IPI can be improved signifi-
cantly by the routine use of immunophenotyping on stag-
ing bone marrow biopsy.
￿ Immunophenotyping i.e. flow cytometry and immuno-
histochemistry should be recommended as routine inves-
tigations on all bone marrows at initial diagnosis, as the
detection of occult disease in morphologically normal
marrow affects clinical outcome in DLBCL.
￿ In this study, molecular analysis did not further contrib-
ute in improving the prognostic significance of the IPI.
This is likely to have been due to technical limitations.
￿ Larger prospective studies are warranted to assess the
impact of staging investigations including gene rearrange-
ment studies on the IPI in a more homogenously treated
DLBCL population.
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